GSK ends $150M licensing deal with Unigene, cue tough questions
Unigene Laboratories is looking for a new partner to commercialize its oral formulation of recombinantly produced parathyroid hormone osteoporosis drug for postmenopausal women after GlaxsoSmithKline (NYSE:GSK) decided to end a nine-year-old licensing deal with the Boonton, New Jersey drug developer. Unigene hosted a conference call following the announcement in which CEO Ashleigh Palmer was forced to […]